Reaction

Metastases To Adrenals reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 907 reports · 44 co-occurring drugs

As of the last recalculation, Metastases To Adrenals appears in 907 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 62.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gefitinib	24	62.6	62.8
Sorafenib	51	59.6	59.8
Durvalumab	40	47.2	47.2
Regorafenib	22	44.5	44.6
Goserelin	21	36.7	36.8
Pemetrexed	31	34.3	34.4
Osimertinib	40	29.9	29.9
Pemetrexed Disodium	47	29.8	29.8
Exemestane	27	29.8	29.8
Fulvestrant	39	28.3	28.3
Pazopanib Hydrochloride	32	28.1	28.1
Everolimus	57	27.4	27.4
Dabrafenib	23	25.7	25.7
Letrozole	60	23.9	23.9
Trametinib	24	23.4	23.4
Letrozole Tablets	44	22.0	22.0
Atezolizumab	32	19.6	19.6
Capecitabine	68	18.4	18.4
Docetaxel Anhydrous	47	16.8	16.8
Docetaxel	47	16.8	16.8
Everolimus Tablets	12	16.6	16.6
Cisplatin	53	16.5	16.5
Prochlorperazine Maleate	6	15.0	15.0
Gemcitabine	25	14.9	15.0
Erlotinib Hydrochloride	8	14.8	14.8
Carboplatin	75	14.7	14.7
Zoledronic Acid	25	14.7	14.7
Crizotinib	8	14.6	14.6
Erlotinib	6	14.3	14.3
Fam-Trastuzumab Deruxtecan-Nxki	6	13.7	13.8
Ado-Trastuzumab Emtansine	5	13.7	13.7
Paclitaxel (Aibumin-Bound)	44	12.9	12.9
Cabozantinib	26	12.8	12.8
Etoposide	37	12.0	12.0
Axitinib	10	11.9	11.9
Gemcitabine Hydrochloride	26	11.5	11.6
Ipilimumab	21	11.4	11.4
Pertuzumab	13	11.1	11.1
Paclitaxel	45	10.9	10.9
Sunitinib Malate	18	10.7	10.7
Bevacizumab	51	10.0	10.0
Nivolumab	39	9.6	9.6
Lapatinib	6	8.9	8.9
Palbociclib	27	6.7	6.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.